X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (74) 74
oncology (73) 73
immunotherapy (69) 69
humans (68) 68
cancer (63) 63
female (29) 29
life sciences (29) 29
male (25) 25
tumors (25) 25
patients (24) 24
melanoma (23) 23
animals (20) 20
immunology (19) 19
neoplasms - immunology (19) 19
adult (17) 17
immunotherapy - methods (17) 17
[ sdv.can ] life sciences [q-bio]/cancer (16) 16
immune checkpoint (16) 16
middle aged (16) 16
pembrolizumab (15) 15
cell death (14) 14
clinical trials (14) 14
therapy (14) 14
apoptosis (13) 13
child (13) 13
lymphocytes (13) 13
metastasis (13) 13
metastatic melanoma (13) 13
pediatrics (13) 13
regulatory t-cells (13) 13
antibodies, monoclonal - therapeutic use (12) 12
antineoplastic agents - therapeutic use (12) 12
care and treatment (12) 12
ipilimumab (12) 12
monoclonal antibodies (12) 12
neoplasms (12) 12
neoplasms - drug therapy (12) 12
nivolumab (12) 12
solid tumors (12) 12
aged (11) 11
expression (11) 11
hematology, oncology and palliative medicine (11) 11
immune system (11) 11
mutation (11) 11
t-cells (11) 11
chemotherapy (10) 10
hematology (10) 10
ligands (10) 10
lymphocytes t (10) 10
medical research (10) 10
metastases (10) 10
pd-l1 protein (10) 10
prognosis (10) 10
survival (10) 10
treatment outcome (10) 10
adolescent (9) 9
antibodies (9) 9
antineoplastic agents - adverse effects (9) 9
blockade (9) 9
hepatitis (9) 9
lymphoma (9) 9
neoplasms - therapy (9) 9
neuroblastoma (9) 9
pd-1 blockade (9) 9
[sdv.can]life sciences [q-bio]/cancer (8) 8
antigens (8) 8
b7-h1 antigen - antagonists & inhibitors (8) 8
biochemistry (8) 8
cell line, tumor (8) 8
cytotoxicity (8) 8
lung cancer (8) 8
lymphomas (8) 8
nk cells (8) 8
pd-1 protein (8) 8
retrospective studies (8) 8
young adult (8) 8
advanced melanoma (7) 7
adverse events (7) 7
aged, 80 and over (7) 7
analysis (7) 7
breast-cancer (7) 7
cancer therapies (7) 7
cancer-immunotherapy (7) 7
dendritic cells (7) 7
drug therapy (7) 7
gene expression (7) 7
immune response (7) 7
immunomodulation (7) 7
immunotherapy - adverse effects (7) 7
infant (7) 7
mice (7) 7
molecular targeted therapy (7) 7
programmed cell death 1 receptor - antagonists & inhibitors (7) 7
programmed cell death 1 receptor - immunology (7) 7
radiotherapy (7) 7
t cells (7) 7
chemistry (6) 6
child, preschool (6) 6
children (6) 6
corticoids (6) 6
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Cancer, ISSN 0959-8049, 05/2017, Volume 77, p. 165
The Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 system [3] classifies PSPD as a progression and is thus not adapted to the atypical responses... 
Regulatory agencies | Evaluation | Immunotherapy | Melanoma | Confusion | Criteria | Solid tumors | Lesions | Tumors | Guidelines | Cancer
Journal Article
01/2018, 1st ed. 2018, ISBN 9783319434841, 300
This book provides a comprehensive overview of current immunotherapy strategies, and how these may be applicable to childhood cancers. The first part of the... 
Cancer-Immunotherapy | Cancer in children | Pediatrics | Oncology | Immunology | Medicine & Public Health
eBook
Bulletin du Cancer, ISSN 0007-4551, 12/2018, Volume 105, pp. S121 - S131
Alternative Immunotherapies: Monoclonal antibodies targeted at immune checkpoint molecules such as PD-1, PD-L1, and CTLA-4 have revolutionized the field of... 
Immunotherapy | Cancer
Journal Article
JAMA DERMATOLOGY, ISSN 2168-6068, 01/2018, Volume 154, Issue 1, pp. 113 - 113
The article by Rivera et al is the first report of a previously undescribed side effect of checkpoint inhibitors: hair repigmentation (HR). In this significant... 
REGULATORY T-CELLS | DERMATOLOGY | Hair | B7-H1 Antigen | Humans | Immunotherapy | Cell Death | Programmed Cell Death 1 Receptor | Lung Neoplasms | Life Sciences | Human health and pathology | Immunology | Dermatology | Cancer
Journal Article
Pediatric Blood & Cancer, ISSN 1545-5009, 08/2015, Volume 62, Issue 8, pp. 1317 - 1325
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2013, Volume 19, Issue 19, pp. 5261 - 5263
Systemic administration of the checkpoint blockade antibody anti-CTLA4 results in severe autoimmune toxicity, limiting its clinical efficacy. Fransen and... 
ONCOLOGY | CANCER-IMMUNOTHERAPY | AGE | Animals | Neoplasms - immunology | Humans | Antibodies, Blocking - immunology | Female | CD8-Positive T-Lymphocytes - immunology | CTLA-4 Antigen - antagonists & inhibitors | CTLA-4 Antigen - immunology | Neoplasms - pathology | Antibodies, Monoclonal - immunology
Journal Article
JAMA Dermatology, ISSN 2168-6068, 01/2018, Volume 154, Issue 1, p. 113
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 10/2017, Volume 76, Issue 10, pp. 1747 - 1750
ObjectivesImmune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1 (PD-1) have... 
MELANOMA | MANAGEMENT | TOXICITIES | LEAGUE | COLLEGE | RHEUMATOLOGY | NIVOLUMAB | BLOCKADE | CLASSIFICATION CRITERIA | CANCER | IPILIMUMAB | Antibodies, Monoclonal, Humanized - adverse effects | Polymyalgia Rheumatica - blood | Polymyalgia Rheumatica - chemically induced | Arthritis, Rheumatoid - blood | Humans | Ipilimumab | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Peptides, Cyclic - immunology | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Arthritis, Rheumatoid - chemically induced | Polymyalgia Rheumatica - drug therapy | B7-H1 Antigen - antagonists & inhibitors | Antineoplastic Agents - adverse effects | Arthritis, Rheumatoid - drug therapy | Aged, 80 and over | Antibodies - blood | Female | Aged | Retrospective Studies | CTLA-4 Antigen - antagonists & inhibitors | Corticoids | Disease | PD-1 protein | Arthralgia | Lung cancer | Clinical trials | Antibodies | Cytotoxicity | Mesothelioma | Lymphocytes T | Metastasis | Cancer therapies | Immunosuppressive agents | Proteins | Immunotherapy | Rheumatism | Immunoglobulins | Antiinflammatory agents | Cell survival | Psoriasis | Internal medicine | Rheumatic diseases | Rheumatology | Melanoma | Inflammation | Citrulline | Patients | Rheumatoid factor | Immune checkpoint | Cell death | Rheumatoid arthritis | Collaboration | Polymyalgia rheumatica | Ligands | Autoimmune diseases | Apoptosis | Cancer
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 03/2019, Volume 129, Issue 3, pp. 1211 - 1228
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 12/2018, Volume 15, Issue 12, pp. 748 - 762
Anti-PD-1/PD-L1 monoclonal antibodies have substantially improved the overall survival of a subset of patients across multiple solid tumour types, but other... 
BONE-SCAN | LUNG-CANCER PATIENTS | ONCOLOGY | PD-1 BLOCKADE | IFN-GAMMA | REGULATORY T-CELLS | ACQUIRED-RESISTANCE | OPEN-LABEL | SCAN FLARE PHENOMENON | TUMOR-GROWTH RATE | IMMUNE-CHECKPOINT BLOCKADE | Cell activation | Immune checkpoint | PD-1 protein | Immunoregulation | Biopsy | PD-L1 protein | Monoclonal antibodies | Lymphocytes T | Solid tumors | Patients
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 06/2013, Volume 123, Issue 6, pp. 2447 - 2463
Activation of TLR9 by direct injection of unmethylated CpG nucleotides into a tumor can induce a therapeutic immune response; however, Tregs eventually inhibit... 
MEDICINE, RESEARCH & EXPERIMENTAL | IMMUNITY | ENTEROPATHY | EFFICACY | REGULATORY T-CELLS | LYMPHOMA | CANCER-IMMUNOTHERAPY | MODEL | MONOCLONAL-ANTIBODIES | BLOCKADE | IPILIMUMAB | Care and treatment | Immunotherapy | Physiological aspects | Monoclonal antibodies | Genetic aspects | Research | Cancer | Lymphomas | Lymphocytes | Tumors | Immune system
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 03/2016, Volume 126, Issue 3, pp. 921 - 937
Journal Article